NCT02057718Phase 2Completed

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis

Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-05-08Actual
Enrollment · participants33Actual
Source updated2023-10-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.